Skip to main content
S&P 5007,688.62+1.58%DOW53,356.12+3.03%NASDAQ25,736.51+1.44%BTC$80,787.00+5.07%ETH$2,431.65+7.47%GOLD$4,134.30+1.51%OIL$87.17-1.08%
Smart Investors Daily
SID Premium
IN

NASDAQ · INMB

INmune Bio, Inc.

Healthcare · Biotechnology

$1.33

Up+$0.01 (+0.76%)

Updated Nov 5, 2026, 3:08 AM

SID Score

4.1/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
56.63M
P/E ratio
-1.14
Dividend yield
0.00%
52-week range
$1.09 – $2.60
Volume
258.64K
Avg. volume
455.95K

Price performance · INMB

INMB price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 4, 2026

INMB closed at $1.33 after 21 trading sessions, down 28.49% for the selected period.

Last close
$1.33
Period change
-28.49%
Period low
$1.32
Period high
$1.89
Daily close
View OHLC price history
INMB OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 4, 2026$1.35$1.40$1.28$1.33258.64K
Nov 3, 2026$1.40$1.42$1.30$1.32235.73K
Nov 2, 2026$1.47$1.49$1.365$1.38203.57K
Oct 30, 2026$1.53$1.555$1.43$1.45184.1K
Oct 29, 2026$1.53$1.65$1.53$1.60185.89K
Oct 28, 2026$1.50$1.53$1.46$1.53188.54K
Oct 27, 2026$1.41$1.53$1.40$1.52274.78K
Oct 26, 2026$1.47$1.49$1.41$1.43162.79K
Oct 23, 2026$1.53$1.53$1.45$1.46190.56K
Oct 22, 2026$1.58$1.63$1.52$1.54220.7K
Oct 21, 2026$1.61$1.69$1.60$1.61229.97K
Oct 20, 2026$1.53$1.63$1.53$1.6075.6K
Oct 19, 2026$1.58$1.58$1.5101$1.54156.58K
Oct 16, 2026$1.68$1.68$1.56$1.57196.17K
Oct 15, 2026$1.60$1.68$1.53$1.65628.02K
Oct 14, 2026$1.70$1.915$1.59$1.601.14M
Oct 13, 2026$1.77$1.79$1.64$1.68247.32K
Oct 12, 2026$1.89$1.89$1.78$1.7872.74K
Oct 9, 2026$1.84$1.91$1.84$1.8991.63K
Oct 8, 2026$1.85$1.87$1.79$1.83379.17K
Oct 7, 2026$1.82$1.88$1.82$1.86104.38K

Latest INMB news

The latest Smart Investors Daily articles mentioning INMB.

Stock researchCompany · Overview

INMB research

Overview

Company profile and research snapshot.

Company profile

INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products include INKmune, INBO3, XPro1595, LIVNate, and others.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$22.00
Implied upside
—
Analysts
—
INMB recent ratings
DateFirmRatingTarget
Mar 11, 2026LUCID CAPITAL MARKETSBuy—
Jul 2, 2025Maxim GroupBuy—
Jul 1, 2025BTIGNeutral—
Jul 1, 2025ScotiabankSector Underperform—
Feb 13, 2025Maxim GroupBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 29, 2026

INmune Bio Inc. to Report Third Quarter 2026 Financial Results and Provide Corporate Update on Thursday, November 5th

Management to host conference call and webcast at 4:30 pm ET on that day BOCA RATON, Fla, Oct. 29, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a late-stage biotechnology company focused on inflammation and immunology, today announced t that it will host a conference call on Thursday, November 5th, 2026 at 4:30pm EDT to discuss results for its quarter ended September 30, 2026 and to provide a corporate update. Conference Call Information To participate in this event,

Yahoo · Oct 28, 2026

INmune Bio, Inc. Announces Pricing of $4.50 Million Registered Direct Offering and Concurrent Private Placement

BOCA RATON, Fla., Oct. 28, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the "Company"), a late-stage biotechnology company focused on inflammation and immunology, today announced that it has entered into a definitive agreement with a single healthcare-focused, institutional investor for a registered direct offering of an aggregate of 3,000,000 shares of common stock and a concurrent private placement of unregistered warrants to purchase up to 3,000,000 shares common stock (together,

Yahoo · Oct 21, 2026

Manufacturing Progress Gives INmune Bio a Clearer UK Filing Path for Ebstrocel

INmune Bio (NASDAQ:INMB) is advancing its European commercialization strategy for Ebstrocel, leveraging chemistry, manufacturing, and controls (CMC) progress to streamline its regulatory timeline and accelerate potential entry into the UK market. By submitting its final pre-marketing authorization application (pre-MAA) package to the UK’s Medicines and Healthcare products Regulatory Agency (MHRA), the biotechnology company confirmed a major pivot: it will bypass a rolling submission in favour of

Yahoo · Oct 21, 2026

INmune Bio Advances Ebstrocel™ Toward Potential UK Approval in Mid-2027

Final pre-MAA package submitted to MHRA on October 20, 2026Full MAA submission targeted for early February 2027, under a revised strategy that could bring potential UK approval forward by approximately six weeksU.S. BLA expected to be submitted in Q2, 2027 BOCA RATON, Fla., Oct. 21, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a late-stage biotechnology company focused on inflammation and immunology, today announced that it has submitted its final pre-Marketing Author

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By